KR20240072133A - 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 - Google Patents

향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 Download PDF

Info

Publication number
KR20240072133A
KR20240072133A KR1020247007349A KR20247007349A KR20240072133A KR 20240072133 A KR20240072133 A KR 20240072133A KR 1020247007349 A KR1020247007349 A KR 1020247007349A KR 20247007349 A KR20247007349 A KR 20247007349A KR 20240072133 A KR20240072133 A KR 20240072133A
Authority
KR
South Korea
Prior art keywords
disorder
disorders
methylone
anxiety
neuropsychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247007349A
Other languages
English (en)
Korean (ko)
Inventor
블레이크 만델
마틴 스토그뉴
제니퍼 루이즈 슈미트
마커스 실리그
Original Assignee
트랜센드 테라퓨틱스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트랜센드 테라퓨틱스 인코퍼레이티드 filed Critical 트랜센드 테라퓨틱스 인코퍼레이티드
Publication of KR20240072133A publication Critical patent/KR20240072133A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020247007349A 2021-08-06 2022-08-01 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 Pending KR20240072133A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163230237P 2021-08-06 2021-08-06
US63/230,237 2021-08-06
US202163240113P 2021-09-02 2021-09-02
US63/240,113 2021-09-02
US202163255706P 2021-10-14 2021-10-14
US63/255,706 2021-10-14
US202263325757P 2022-03-31 2022-03-31
US63/325,757 2022-03-31
US202263328343P 2022-04-07 2022-04-07
US63/328,343 2022-04-07
PCT/US2022/074369 WO2023015154A1 (en) 2021-08-06 2022-08-01 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Publications (1)

Publication Number Publication Date
KR20240072133A true KR20240072133A (ko) 2024-05-23

Family

ID=85156410

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247007349A Pending KR20240072133A (ko) 2021-08-06 2022-08-01 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도

Country Status (10)

Country Link
US (6) US11707446B2 (https=)
EP (1) EP4380588A4 (https=)
JP (1) JP2024530007A (https=)
KR (1) KR20240072133A (https=)
AU (1) AU2022325135A1 (https=)
CA (1) CA3227360A1 (https=)
IL (1) IL310334A (https=)
MX (1) MX2024001654A (https=)
TW (1) TW202327571A (https=)
WO (1) WO2023015154A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254190A2 (en) * 2023-06-06 2024-12-12 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) 2021-08-06 2025-05-13 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12343326B2 (en) 2021-08-06 2025-07-01 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
MX2024001654A (es) 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
KR20240165982A (ko) * 2022-03-31 2024-11-25 트랜센드 테라퓨틱스 인코퍼레이티드 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
US8575194B1 (en) 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2021257500A1 (en) 2020-06-17 2021-12-23 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
JP2024512796A (ja) * 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
MX2024001654A (es) 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
EP4426685A4 (en) * 2021-11-05 2026-01-07 Terran Biosciences Inc Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use

Also Published As

Publication number Publication date
US20240058301A1 (en) 2024-02-22
WO2023015154A1 (en) 2023-02-09
US20240293357A1 (en) 2024-09-05
EP4380588A1 (en) 2024-06-12
US11969407B2 (en) 2024-04-30
US20230054211A1 (en) 2023-02-23
TW202327571A (zh) 2023-07-16
US12059402B2 (en) 2024-08-13
US20250255846A1 (en) 2025-08-14
CA3227360A1 (en) 2023-02-09
US11707446B2 (en) 2023-07-25
JP2024530007A (ja) 2024-08-14
US12233046B2 (en) 2025-02-25
IL310334A (en) 2024-03-01
EP4380588A4 (en) 2025-10-08
US20260083699A1 (en) 2026-03-26
MX2024001654A (es) 2024-06-28
US20230338333A1 (en) 2023-10-26
AU2022325135A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
KR20240072133A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
TWI553006B (zh) 依託拉嗪(eltoprazine)於治療與神經或心理疾病有關之認知失能之症狀的用途
US20190209520A1 (en) Pharmacological treatment of cognitive impairment
TW202306571A (zh) 確定待投與於個體的致幻劑之劑量或與另一種致幻劑之劑量等效性之方法
US20230270753A1 (en) Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
KR20240165982A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
US20250221957A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40112015A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
US12343326B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40120411A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
US20250332139A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
EP4724433A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
WO2024254190A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
KR20260053276A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
CN118434416A (zh) 精神作用药物及其用于治疗精神和神经病状和病症的用途
Cheung Remission of refractory obsessive–compulsive symptoms in an adolescent with autism spectrum disorder: A case report and a review on synaptic plasticity
AU2016219678B2 (en) Pharmacological treatment of cognitive impairment
JP2007512289A (ja) 不安処置のための（＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240304

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250703

Comment text: Request for Examination of Application